Now live: Pro — the full 13F research suite for serious investorsSee pricing →
M28 Capital Management LP

Q4 2023 · 13F-HR

M28 Capital Management LPholdings as filed

Filed 2024-02-12 · accession 0000902664-24-001422

$120.7M
Reported value
10
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
Y95308105WVEWAVE LIFE SCIENCES LTD$37.2M30.8%7,373,413CommonSOLE
00534A102IVVDINVIVYD INC$36.4M30.2%9,248,250CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$15.7M13.0%523,280CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$6.3M5.24%363,800CommonSOLE
231269309CRISCURIS INC$5.4M4.46%421,951CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$5.2M4.32%142,800CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$4.9M4.05%121,200CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$3.8M3.13%1,910,600CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$3.7M3.06%216,600CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$2.1M1.71%67,400CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.